Mono- and combinational drug therapies for global viral pandemic preparedness

Broadly effective antiviral therapies must be developed to be ready for clinical trials, which should begin soon after the emergence of new life-threatening viruses. Here, we pave the way towards this goal by reviewing conserved druggable virus-host interactions, mechanisms of action, immunomodulatory properties of available broad-spectrum antivirals (BSAs), routes of BSA delivery, and interactions of BSAs with other antivirals. Based on the review, we concluded that the range of indications of BSAs can be expanded, and new pan- and cross-viral mono- and combinational therapies can be developed. We have also developed a new scoring algorithm that can help identify the most promising few of the thousands of potential BSAs and BSA-containing drug cocktails (BCCs) to prioritize their development during the critical period between the identification of a new virus and the development of virus-specific vaccines, drugs, and therapeutic antibodies.Peer reviewe

Application of Milk Permeate as an Inducer for the Production of Microbial Recombinant Lipolytic Enzymes

Recombinantly produced enzymes are applied in many fields, ranging from medicine to food and nutrition, production of detergents, textile, leather, paper, pulp, and plastics. Thus, the cost-effectiveness of recombinant enzyme synthesis is an important issue in biotechnological industry. Isopropyl-β-D-thiogalactoside (IPTG), an analog of lactose, is currently the most widely used chemical agent for the induction of recombinant enzyme synthesis. However, the use of IPTG can lead to production of toxic elements and can introduce physiological stress to cells. Thus, this study aims to find a simpler, cheaper, and safer way to produce recombinant enzymes. In this study, production of several previously designed recombinant lipolytic enzymes (GDEst-95 esterase, GD-95RM lipase, fused GDEst-lip lipolytic enzyme, and putative cutinase Cut+SP from Streptomyces scabiei 87.22) is induced in E. coli BL21 (DE3) using 4 mM milk permeate, a type of waste of the milk manufacturing process possessing >82% lactose. The SDS-PAGE analysis clearly indicates synthesis of all target enzymes during a 2–12 h post-induction timeframe. Further investigation of GDEst-95, GD-95RM, GDEst-lip, and Cut+SP biocatalysts was carried out spectrophotometrically and using zymography method, confirming production of fully active enzymes

Biosynthesis of Silver Nanoparticles Produced Using <i>Geobacillus</i> spp. Bacteria

Silver nanoparticles (AgNPs) are well known for their unique physical and chemical properties, which can be incorporated into a wide range of applications. The growing resistance of microorganisms to antimicrobial compounds promoted the use of AgNPs in antimicrobial therapy. AgNPs can be obtained using physical and chemical methods, but these technologies are highly unfriendly to nature and produce large amounts of side compounds (for example, sodium borohydride and N,N-dimethylformamide). Therefore, alternative technologies are required for obtaining AgNPs. This report focuses on the biosynthesis of silver nanoparticles through the reduction of Ag+ with the cell-free secretomes of four Geobacillus bacterial strains, namely, 18, 25, 95, and 612. Only a few studies that involved Geobacillus bacteria in the synthesis of metal nanoparticles, including AgNPs, have been reported to date. The silver nanoparticles synthesized through bio-based methods were characterized using UV–Vis spectroscopy, scanning electron microscopy (SEM), dynamic light scattering (DLS), and zeta potential measurements. UV–Vis spectroscopy showed a characteristic absorbance peak at 410–425 nm, indicative of AgNPs. SEM analysis confirmed that most nanoparticles were spherical. DLS analysis showed that the sizes of the obtained AgNPs were widely distributed, with the majority less than 100 nm in diameter, while the zeta potential values ranged from −25.7 to −31.3 mV and depended on the Geobacillus spp. strain